Cutaneous Melanoma: An Updated Sign Guideline

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 55: Solar and Ultraviolet Radiation. Lyon: International Agency for Research on Cancer; 1992. http://monographs.iarc.fr/ENG/Monographs/vol55/index.php (accessed 26/07/17).

Information Services Division. Cancer Incidence in Scotland (2013). Edinburgh: Information Services Division; 2015. http://www.isdscotland.org/Health-Topics/Cancer/Publications/2015-04-28/2015-04-28-Cancer-Incidence-Report.pdf? (accessed 26/07/17).

Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developer's handbook. November 2011. http://www.sign.ac.uk/assets/sign50_2011.pdf (accessed 26/07/17).

Scottish Intercollegiate Guidelines Network. SIGN 146: Cutaneous melanoma. January 2017. http://www.sign.ac.uk/sign-146-melanoma.html (accessed 26/07/17).

Healsmith MF , Bourke JF , Osborne JE . An evaluation of the revised seven-point checklist for the early diagnosis of cutaneous malignant melanoma. Br J Dermatol 1994; 130: 48–50.

Fitzpatrick TB , Rhodes AR , Sober AJ . Primary malignant melanoma of the skin: the call for action to identify persons at risk; to discover precursor lesions; to detect early melanomas. Pigment Cell 1988; 9:7.

Balch CM , Soong SJ , Gershenwald JE . Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622–34.

Morton DL , Wen DR , Wong JH . Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392–9.

National Institute for Health and Care Excellence. Melanoma: assessment and management. London: NICE; 2015. https://www.nice.org.uk/guidance/ng14 (accessed 26/07/17). [NICE guidance is prepared for the NHS in England, and is subject to regular review and may be updated or withdrawn. NICE has not checked the use of its content in this publication to confirm that it accurately reflects the NICE publication from which it was taken.]

Pflugfelder A , Kochs C , Blum A . Malignant melanoma S3 -guideline ‘diagnosis, therapy and follow-up of melanoma’. J Dtsch Dermatol Ges 2013; 11 (Suppl 6):1–116.

Robert C , Karaszewska B , Schachter J . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30–9.

Hodi FS , O'Day SJ , McDermott DF . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.

Robert C , Schachter J , Long GV . Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 25: 2521–32.

Larkin J , Chiarion-Sileni V , Gonzalez R . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015:1270–1.

Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 2015; 161: 1681–96.